A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria

NCT01756703 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Nephropathy

Interventions

DRUG: MT-3995 Low
DRUG: MT-3995 High
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation